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Abstract
Objective and design Atherosclerosis (ATH) is a chronic
inflammatory disease that involves cascades of signaling
events mediated by various effector proteins. Here we
sought to determine if the expression of Wnt5a, a secreted
glycoprotein, is altered in discrete regions of the arterial
plaque.
Methods Atherosclerotic plaque tissues from 14 human
subjects undergoing elective carotid endarterectomy were
used in this study. Immunohistochemistry and laser capture
microdissection combined with quantitative real-time PCR
were used to determine the expression of Wnt5a and Toll-
like receptors (TLRs) in different sections of the arterial
lesions. Atherosclerotic serum samples (n = 30) and serum
from healthy subjects (n = 16) were quantified for Wnt5a
using an enzyme-linked immunosorbent assay (ELISA).
Results The data analysis revealed that Wnt5a transcripts
and protein were elevated in advanced arterial lesions
relative to less advanced arterial lesions; that Wnt5a
expression correlated with the presence of TLR4 and TLR2
transcripts; and that the average amount of Wnt5a protein
present in atherosclerotic patient serum was significantly
higher compared to healthy controls.
Conclusions This study is the first to provide evidence
that the expression of Wnt5a increases as the disease pro-
gresses to a more advanced stage, and that this expression
is coincident with that of TLR2 and TLR4. In addition, we
found that the average Wnt5a levels in the serum of ath-
erosclerotic patients are elevated relative to healthy
controls, which is consistent with the hypothesis that
Wnt5a plays a role in ATH.
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Introduction
Atherosclerosis (ATH) is a highly prevalent chronic sys-
temic inflammatory disease [1]. A hallmark of ATH is the
accumulation of distinct cell types (e.g. macrophages,
smooth muscle cells and foam cells) in the arterial wall,
along with a buildup of lipids, cholesterol, calcium, and
cellular debris within the intima of large-sized and med-
ium-sized muscular arteries. This process leads to the
formation of fatty streaks, atheromas, or atherosclerotic
plaques that have a potential to rupture, causing compli-
cations such as a stroke, myocardial infarction or peripheral
vascular ischemia [2–4].
Monocytes/macrophages are the predominant types of
immune cells in atherosclerotic plaques, and are known to
significantly modify their local environment. Specifically,
activated macrophages secrete different types of effector
proteins (e.g., cytokines such as tumor necrosis factor-a,
interleukin-12 and -18, chemokines like CCL3, CCL4) that
can act on the macrophages themselves or on other local
cell types (e.g. smooth muscle cells). The secretion of an
initial set of proteins and their autocrine/paracrine effects
can trigger a second wave of effector molecules that may
favor the development of a severe plaque [5]. In this
manner, cascades of signaling events transpire during
ATH, mediated to a large extent by these potent effector
proteins. Determining which effector proteins are present,
and their location within a plaque, gives insights into the
mechanisms of ATH and may suggest novel approaches to
diagnosing and staging atherosclerotic plaques.
Wnts are a family of highly conserved, secreted glyco-
proteins that are involved in many biological processes
such as cell fate, polarity and differentiation [6]. Over the
last decade, Wnts have also been implicated in a variety of
clinical conditions, including pathological inflammation
[7–9]. Our research specifically focuses on Wnt5a, which
has been implicated in rheumatoid arthritis [10], sepsis
[11], and tuberculosis [7]. Wnt5a activity in pathological
inflammation has been linked to Toll-like receptors
(TLRs), a family of transmembrane signaling proteins that
trigger the innate immune response [7, 12]. In particular,
TLR4 and TLR2 have been implicated in the pathogenesis
of ATH [13–16]. Recently, our group demonstrated that
Wnt5a is specifically expressed in the macrophage-rich
regions of murine and human atherosclerotic lesions, and
that this expression was coincident with that of TLR4 [17].
We also demonstrated that Wnt5a transcripts are induced in
murine macrophages upon stimulation with lipopolysac-
charide (a trigger for TLR4 signaling) [17], and that
oxidized-LDL stimulation of human monocytes/macro-
phages leads to increased expression of Wnt5a transcripts,
indicating that macrophages are a source of Wnt5a in
ATH [18].
Combined, the above observations led us to the
hypothesis that Wnt5a is important in the pathogenesis of
ATH, and that the expression of Wnt5a is linked to TLR. In
order to probe our hypothesis more extensively and rigor-
ously, we employed laser capture microdissection (LCM)
combined with quantitative real-time PCR (RT-PCR), in
addition to immunohistochemical analysis. By using LCM
and quantitative RT-PCR, an additional and rigorous test of
coincident expression of TLR4 and TLR2 with Wnt5a
mRNA can be conducted, since the expression of each of
these transcripts in discrete regions can be compared. We
found that the expression of Wnt5a increases as the disease
progresses to a more advanced state, and this expression is
coincident with that of TLR2 and TLR4. Finally, we
speculated that Wnt5a protein might be elevated in serum
isolated from atherosclerotic patients. Thus, we compared
the serum levels of Wnt5a in patients undergoing elective
carotid endarterectomy to serum isolated from healthy
controls, and found that the levels of Wnt5a were, on
average, higher in the atherosclerotic patient samples.
Methods
Source and handling of human atherosclerotic tissue
and serum prior to analysis
Atherosclerotic plaque tissue and peripheral blood were
obtained from 14 and 30 human subjects, respectively,
undergoing elective carotid endarterectomy at Riverside
Methodist Hospital, Columbus, OH from 2009 to 2011. All
samples were obtained and used in compliance with the
approval of the Institutional Review Board for Human
Subjects Committee at Ohio University and Riverside
Methodist Hospital. Based on gross examination, each
fresh tissue sample was divided into fragments that con-
tained well-developed plaques and fragments where the
wall of the artery looked less affected or even normal; both
tissue fragments were processed separately. The samples
were immediately fixed with 10 % buffered formalin
overnight. Subsequently, samples were dehydrated in
sequential alcohol/xylene washes and embedded in paraf-
fin. Serum separation was performed from fresh whole
blood, and collected serum was stored at -80 C until
further use. Clinical data are summarized in Table 1.
Hematoxylin and eosin (H&E) staining
Tissue blocks were sectioned into 5 lm sections and ana-
lyzed using hematoxylin & eosin (H&E) staining. The
microanatomy of the tissue section revealed by the H&E
staining was used to classify the tissue according to the
American Heart Association guidelines [19, 20]. Briefly,
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tissues with smaller lipid cores, a low number of foam
cells, limited or no calcification and no complications (e.g.
no fissures) were classified as less advanced. In contrast,
plaques with a larger lipid core, substantial amount of
inflammation (e.g. foam cells, lymphocytes, and/or giant
macrophages), calcification, and other complications were
graded as more advanced lesions. In an effort to control for
variations in the tissue, the three analytical approaches
used in this study, i.e. H&E, RT-PCR, and immunohisto-
chemistry were conducted on tissue sections sequential to
one another.
Laser capture microdissection (LCM) and RNA
extraction
Prior to slide preparation, all the equipment was cleaned to
minimize any potential RNase contamination. To isolate
total RNA from the microdissected tissues, paraffin blocks
were sectioned into 8 lm sections using a rotary micro-
tome. The first three sections were discarded and
subsequent sections were removed from the microtome and
put in a water bath with RNase free water. Afterwards,
each section was mounted on a polyethylene naphthalene
membrane slide (Leica, Wetzlar, Germany). Subsequently,
the sections were deparaffinized in xylenes and rehydrated
in graded alcohols (100, 90, and 70 % ethanol). The sec-
tions were then stained using H&E, and dissected using
Leica LMD6000 (Wetzlar, Germany) according to the
manufacturer’s instructions. The areas of interest for
microdissection and RNA extraction were: region 1—less
advanced region of the arterial wall; region 2—shoulder of
the lesion usually containing a high number of foam cells;
region 3—fibrous cap; and region 4—plaque/intima. RNA
from the dissected tissue was extracted using Qiagen
miRNeasy FFPE Kit according to the manufacturer’s
instructions (Qiagen, Valencia, CA, USA). RNA was
quantified, and reverse transcribed using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA).
Quantitative RT-PCR
Human HPRT1, Wnt5a, TLR4 and TLR2 transcripts were
quantified using ABI Step One Plus quantitative RT-PCR
(Applied Biosystems) for the LCM samples. Taqman Gene
Expression Assays GEx (Hs99999909_m1 HPRT1,
Hs00180103_m1 Wnt5a, Hs00152939_m1 TLR4, and
Hs00610101_m1 TLR2) and Taqman Gene Expression
Master Mix (Applied Biosystems) were used according to
the manufacturer’s protocol. The thermal-cycler conditions
were: 1 cycle of 95 C for 10 min, 40 cycles of 95 C for
15 s, 60 C for 1 min. Comparative Delta Ct method was
used to obtain fold expression of Wnt5a, TLR4 and TLR2
relative to HPRT1 endogenous control.
Immunohistochemistry
Consecutive 5 lm sections from each block were placed on
a single slide for immunostaining. One section served as an
isotype-matched control for the other section on the same
slide. Immediately prior to staining, sections were placed in
an incubator at 60 C for 1 h, and deparaffinized/rehy-
drated in xylenes/graded alcohol. After antigen retrieval in
10 mM citrate buffer pH 6.0, the sections were blocked
with 3 % hydrogen peroxide followed by 1 % bovine
serum albumin (Sigma Aldrich, St. Louis, MO, USA).
Wnt5a was detected with monoclonal mouse anti-human
Wnt5a (Abcam, Cambridge, MA, USA), while the isotype-
matched control tissues were stained with normal mouse
IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA). These tissues were then incubated with HRP con-
jugated secondary sheep anti-mouse IgG (Amersham
Biosciences, UK). DAB enhanced liquid substrate (Sigma
Aldrich) was added for visualization. Subsequently, the
slides were counter-stained with hematoxylin.
Wnt5a enzyme-linked immunosorbent assay (ELISA)
Atherosclerotic serum samples were obtained from 30
human subjects undergoing elective carotid endarterec-
tomy at Riverside Methodist Hospital, Columbus, OH,
USA. Normal control serum (n = 16) was either obtained
from healthy volunteers with informed consent, or pur-
chased from Bioserve (Beltsville, MD, USA). All samples
were obtained and used in compliance with the Institutional
Review Board for Human Subjects Committee at Ohio
University and Riverside Methodist Hospital. Commer-
cially available Wnt5a ELISA kit (USCN Life Science
Inc., Burlington, NC) was used to detect the expression of
Table 1 Clinical and pathological characteristics
Total patients n = 30
Age range 43–90 years
Average 68.2 (SD 11.3)
Gender M/F 13/17
BMI range 21.6–35.6




Other inflammatory disease 15/30
Statin treatment 22/30
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Wnt5a protein in the serum samples. The ELISA was
performed according to the manufacturer’s protocol.
Statistical analyses
Comparisons between different areas in the arterial wall
were conducted using a Nonparametric test (Wilcoxon
test), and the significance level was set to 0.05. Data for
Wnt5a protein from a single serum sample is expressed as
mean of duplicate samples. An unpaired student’s t-test
was performed for comparison between the control and
atherosclerotic serum samples. Correlation between Wnt5a
serum levels, as measured by ELISA and clinical donor
characteristics, was assessed using linear regression for age
and body mass index (BMI), and Welch’s modified t-tests
for gender, diabetes, cancer, inflammatory disease, and
statin treatment. All tests were performed two-tailed with
the typical 5 % significance level. Data were expressed as
mean ± SD.
Results
Wnt5a mRNA transcripts are elevated in diseased
regions of atherosclerotic arteries relative to the less
advanced regions of the arteries
Carotid artery segments, removed during elective endar-
terectomy, were obtained. A typical segment is shown in
Fig. 1a, which reveals extensive plaque within the artery.
These segments of the artery were formalin fixed, paraffin
embedded and sectioned. A typical H&E staining of a less
advanced arterial tissue and of an atherosclerotic plaque is
shown in Fig. 1b and c, respectively. Figure 1c presents an
axial view of roughly 50 % of the artery. The large white
space subtended by the tissue is the lumen of the artery.
The tissue contains four distinct regions: region 1—less
advanced; region 2—shoulder of the lesion usually con-
taining a high number of foam cells; region 3—fibrous cap;
and region 4—plaque/intima.
Figure 2 shows representative sections of human carotid
arterial wall from four different patients used in this study.
Areas of the artery free of plaque or with less evidence of
disease reveal a thin intima with a preserved architecture of
the arterial wall, and were classified as less advanced.
Areas of the artery defined as advanced lesions demon-
strated a fibrous cap, necrotic center, inflammatory cells
and calcifications.
We have previously demonstrated that Wn5a protein is
present in human atherosclerotic tissue [17]. We used the
above described tissue sections to expand this observation.
Specifically, we utilized LCM, in conjunction with quan-
titative RT-PCR, to determine if Wnt5a transcripts are
elevated in regions of the arteries that clearly have plaque
present compared to less advanced regions of the arteries.
Samples were taken, via LCM, from regions 2, 3 and 4,
(depicted in Fig. 1c), and the level of Wnt5a mRNA
determined via quantitative RT-PCR. The average of these
values was compared to that obtained using samples taken
from the less advanced regions of the arteries (region 1 in
Fig. 1c). As shown in Fig. 3a, the average expression
(n = 14) of Wnt5a transcripts is significantly and dramat-
ically higher in regions of the artery that are diseased,
relative to the less advanced regions of the artery
(P \ 0.002). This finding at the mRNA transcript level was
paralleled at the protein level. Specifically, immunohisto-
chemistry revealed significant staining for Wnt5a in










Fig. 1 Example of the carotid artery samples included in this study.
a Gross appearance of the carotid artery removed by endarterectomy
before fixation; Bar 1 cm. b Microscopic view of the H&E staining of
a cross section of the artery at the areas defined as less advanced; Bar
1 mm. c Microscopic view of the H&E staining of the cross-section of
the artery at the areas defined as plaque or advanced; Bar 1 mm.
Regions 1 through 4 show the sections analyzed by LCM/RT-PCR:
region 1—less advanced region of the arterial wall; region 2—
shoulder of the lesion usually containing a high number of foam cells;
region 3—fibrous cap; and region 4—plaque/intima
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regions. As expected, the isotype matched control stained
negative for Wnt5a (Fig. 3b).
We next sought to determine if the expression of Wnt5a
varied between the diseased regions, i.e. between regions 2,
3, and 4 depicted in Fig. 1c, of the plaque. As shown in
Fig. 3c, the average expression (n = 14) of Wnt5a tran-
scripts was significantly elevated in each of the diseased
regions relative to the less advanced regions. Thus, sig-
nificant Wnt5a transcript levels were observed in the
plaque/intima, the fibrous cap (P \ 0.002), and the shoul-
der of the lesion (P \ 0.005). Note that the plaque/intima
region appeared to have the highest level of Wnt5a tran-
scripts. That said, there was also a large amount of
variability in the results from this region, and a statistical
analysis comparing this region to the other diseased regions
revealed no significant differences. The high variability
could be due to the presence of a diverse population of cell
types (e.g. lymphocytes, smooth muscle cells).
TLR4 and TLR2 mRNA transcripts are elevated
in diseased regions of the arteries relative to less
advanced regions of the arteries
We have previously reported coincident TLR4 and Wn5a
protein expression in human atherosclerotic tissue [17]. We
sought to further investigate this observation by assaying
for TLR4 mRNA transcript expression in the carotid artery
samples using LCM and quantitative RT-PCR. We also
assayed for TLR2 in this analysis, since TLR2 has also
been implicated in ATH [14, 21, 22]. As shown in Fig. 4a
and b, respectively, the average expression (n = 14) of
TLR4 and TLR2 transcripts are significantly higher in
regions of the arteries that are diseased, relative to less
advanced regions within the same artery (P \ 0.001).
We next sought to determine if the expression of TLR4
and TLR2 varied between the diseased regions, i.e.
between regions 2, 3, and 4 depicted in Fig. 1c of the
plaque. As shown in Fig. 4c and d, respectively, the
average expression (n = 14) of TLR4 and TLR2 were
significantly elevated in each of the diseased regions rela-
tive to the less advanced regions. Thus, significant TLR4
and TLR2 transcript levels were observed in the plaque/
intima, the fibrous cap, and the shoulder of the lesion
(P B 0.004). As we observed with Wnt5a (Fig. 3c), the
plaque/intima region appeared to have the highest level of
TLR4 and TLR2 transcripts. That said, there was also a
large amount of variability in the results from this region,
and a statistical analysis comparing this region to the other
diseased regions revealed no significant differences. We
suspect that the source of the variability in the plaque/
intima region is due to extensive cellular/molecular heter-
ogeneity within this region of the plaque.
Wnt5a protein in serum isolated from patients
with symptomatic ATH is higher than in serum isolated
from normal subjects
The above observations support our hypothesis that Wnt5a
is present and elevated at sites of ATH and plays a role in
the disease process. Given the increased expression of
Wnt5a, and the fact that Wnt5a is a secreted protein and
present in the vessel wall and thus proximal to the blood
stream, we questioned whether Wnt5a protein might be
elevated in patients suffering from symptomatic ATH.
Thus, we isolated serum from 30 atherosclerotic patients
(14 of whom belonged to the same cohort of patients from
which the tissue samples were drawn) and 16 healthy vol-
unteers. We then quantified the level of Wnt5a protein using
a commercially available Wnt5a ELISA. The average
early lesions advanced lesions
Fig. 2 Examples of H&E staining of carotid artery samples from
patients included in this study. The left panel in the figure is a cross
section of the arterial wall from areas defined as less advanced
lesions, whereas the right panel demonstrates a cross section of the
arterial wall from areas defined as advanced lesions; Bar 1 mm. The
arrow indicates a necrotic center; an inverted triangle indicates the
areas with calcification; a star indicates the fibrous cap region
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Wnt5a protein expression was significantly higher
(P B 0.0005) in serum samples from patients with athero-
sclerotic disease compared to serum samples from healthy
controls (Fig. 5). Interestingly, there appeared to be two
populations of atherosclerotic patients in regards to Wnt5a
expression. Approximately half the population had Wnt5a
protein levels similar to the healthy controls and the other
half had Wnt5a protein levels that were higher than those
observed in healthy controls (Fig. 5). We thus investigated
the presence, or lack thereof, of an effect of clinical char-
acteristics and elevated Wnt5a observed in the serum of
atherosclerotic patients. The clinical/pathological charac-
teristics of the population of patients are summarized in
Table 1. Interestingly, we found that only a previous history
of cancer had a statistically significant (P B 0.01) effect on
the level of Wnt5a present in the serum. Note that five
patients had a previous history of cancer. When Wnt5a
results from these five patients were removed from the
patient population, there was still a statistically significant
difference between the Wnt5a levels observed in the healthy
controls relative to those observed in the atherosclerotic
patients (P B 0.002). This final analysis demonstrates that
the difference between the atherosclerotic patient popula-
tion and the healthy controls was not due to the presence of
cancer in patients in the atherosclerotic population.
Discussion
This study demonstrates that the expression of Wnt5a
transcripts is higher in areas of the arterial wall that show

































































Fig. 3 Quantitative RT-PCR and immunohistochemistry revealed
higher expression of Wnt5a in diseased regions of the atherosclerotic
arteries relative to less advanced regions. LCM was used to obtain
tissue Sections 1–4 described in the ‘‘Materials and methods’’ section.
RNA extracted from these samples was reverse transcribed and
subjected to quantitative RT-PCR. a Mean Wnt5a fold change for 14
different human subjects relative to HPRT1 endogenous control.
b Tissue sections generated from the carotid atherosclerotic lesions
(n = 14) were treated with anti-Wnt5a (a) or isotype control (b), and
analyzed by immunohistochemistry for the presence of Wnt5a; Bar
200 lm. c Individual comparison of 14 samples for Wnt5a transcripts
in less advanced regions of the arterial tissue (region 1) compared to
the three different advanced regions, i.e. regions 2, 3 and 4. Results
are expressed as mean ± SEM. *P \ 0.002, #P \ 0.005 compared to
less advanced regions of the arteries, as determined by nonparametric
Wilcoxon test
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advanced human carotid atherosclerotic lesions. This
observation is congruous with the immunohistochemical
data, which revealed increased expression of Wnt5a in the
regions of severely diseased carotid arteries as compared to
less advanced regions within the same artery. In addition,
using LCM together with quantitative RT-PCR, we found
significantly increased expression of Wnt5a transcripts in
region 2—shoulder of the lesion usually containing a high
number of foam cells; region 3—fibrous cap; and region
4—plaque/intima. These findings confirm and extend our
previous study, where we observed increased expression of
Wnt5a protein in murine and human atherosclerotic lesions
mainly consisting of macrophages/foam cells [17].
TLRs, specifically TLR4 and TLR2, have been impli-
cated in ATH, and can be induced by endogenous (e.g.
activated inflammatory cells) or exogenous (e.g. bacteria)
ligands. Both TLR4 and TLR2 have been shown to be
highly expressed in atherosclerotic lesions [13, 17, 22], and
are thought to play a role in atherosclerotic inflammation,
matrix degradation, arterial remodeling, and plaque insta-
bility and rupture [16, 22, 23]. We previously reported co-
localization of TLR4 with Wnt5a at the protein level [17],
and here we report the elevated expression of TLR4 and
TLR2 mRNA in the diseased regions of the arteries relative
to less advanced regions. In order to determine whether the





















































































Fig. 4 Quantitative RT-PCR revealed higher expression of TLR4 and
TLR2 in diseased regions of the atherosclerotic arteries relative to less
advanced regions. RNA isolated (n = 14) from the areas defined in
Fig. 1 was reverse transcribed, and subjected to quantitative RT-PCR
for analyzing the transcription levels of TLR4 (a) and TLR2 (b) in all
four regions using HPRT1 as an endogenous control. Individual
comparison of 14 samples for TLR4 (c) and TLR2 (d) transcripts in
less advanced arterial tissue (region 1) compared to the three different
advanced regions, i.e. regions 2, 3 and 4, was also performed. Results
are expressed as mean ± SEM. $P \ 0.001, *P \ 0.002, €P \ 0.003,
XP \ 0.004 compared to less advanced regions of the arteries, as
determined by nonparametric Wilcoxon test


















Fig. 5 Atherosclerotic patients show increased levels of Wnt5a
protein in their serum. ELISA was used to quantify the level of Wnt5a
protein in serum samples from normal (n = 16) and atherosclerotic
subjects (n = 30). The results are expressed as mean concentration
values (ng/ml) of the duplicate samples. *P B 0.0005 compared to
control serum as determined by unpaired student’s t-test
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regions within a plaque, LCM in conjunction with quan-
titative RT-PCR was used. We found increased expression
of both of these receptors in region 4—plaque/intima
region, although they were also expressed in regions 2 and
3 at a relatively lower concentration.
While increased Wnt5a expression has been reported in
atherosclerotic lesions, the exact role of Wnt5a in this dis-
ease process is still unknown and is an interesting topic of
investigation [17, 18, 24]. Recently, a possible role of Wnt5a
in vascular calcification has been reported [25]. Other
studies have shown that Wnt5a is upregulated in certain
inflammatory diseases (e.g. rheumatoid arthritis, tubercu-
losis, and sepsis), and particularly by activated macrophages
[7, 10, 11, 18, 26]. Additionally, a link between TLR/Wnt5a
signaling pathway activation has been proposed as a possi-
ble mechanism involved in the pathogenesis of these
inflammatory disorders [16, 27–29]. Blumenthal et al. [7]
reported that TLR2 and TLR4 activated by mycobacteria
and lipopolysaccharide, respectively, led to the upregulation
of Wnt5a mRNA expression in human macrophages.
Interestingly, the antagonists for both TLR2 and TLR4 were
shown to inhibit bacteria-induced upregulation of Wnt5a
mRNA [7]. Based on these reports, it seemed plausible to
explore the hypothesis that TLR2, TLR4, and Wnt5a may
participate together in the pathogenesis of ATH. Indeed, our
results demonstrate relatively higher levels of mRNA for
Wnt5a, TLR2, and TLR4 in the diseased regions compared
to the less advanced regions of the artery. Although addi-
tional work is required to ascertain the combined role of
Wnt5a, TLR2 and TLR4 signaling in ATH, our finding of
coincident expression suggests a synergistic role of these
mediators in disease pathogenesis.
Since Wnt5a is a secreted protein, we sought to deter-
mine if Wnt5a could be detected in the serum of human
atherosclerotic patients. We found increased levels of
Wnt5a protein in human atherosclerotic serum samples as
compared to control serum samples, suggesting an active
role of Wnt5a in the pathogenesis of ATH. Interestingly,
approximately half the atherosclerotic population had
Wnt5a protein levels similar to the healthy controls, and
the other half had Wnt5a protein levels higher than those
observed in healthy controls. One plausible interpretation
of the ‘‘bimodal’’ data is that Wnt5a serum levels identify
subpopulations of atherosclerotic patients. A further
investigation into the relationship between Wnt5a in serum
and vascular disease, and its possible clinical implications,
is clearly required and warranted.
In considering the Wnt5a serum results, it is important
to recognize that Wnt5a has been reported to be increased
in other disease settings. For example, Bilkovski et al. [30]
found elevated Wnt5a protein in adipose tissue from obese
and type II diabetic patients, as well as elevated Wnt5a
mRNA in circulating CD14? monocytes isolated from
these patients. The patient population in the present study
contained diabetic patients, as well as patients with other
inflammatory diseases (Table 1). Although we did not find
a correlation between Wnt5a levels and the other diseases
present in the ATH patient population used in this study,
except, as noted, for cancer, the presence of these diseases
does confound our interpretation. Based on the data set we
currently have, we cannot pinpoint the exact clinical cause
for the elevated Wnt5a. That said, our finding that the
Wnt5a levels are statistically higher in atherosclerotic
patients compared to controls is consistent with the
hypothesis that Wnt5a plays a role in ATH.
In conclusion, these results confirm and extend our
previous report that Wnt5a is expressed in atherosclerotic
lesions. This study is the first to provide evidence that the
expression of Wnt5a increases as the disease progresses to
a more advanced stage, and that the expression of Wnt5a,
TLR2, and TLR4 is coincident in the diseased regions. In
addition, we found that the average Wnt5a levels in the
serum of atherosclerotic patients is elevated relative to
healthy controls, which is consistent with the hypothesis
that Wnt5a plays a role in ATH.
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